Season's Savings | ₹5/mo for 3 months

₹199/month after first 3 months. Renews automatically. Terms apply.
PEPtalk cover art

PEPtalk

PEPtalk

Written by: Jake & Cynthia
Listen for free

About this listen

A twice-weekly, AI-hosted podcast on the peptide market. Mondays: deep dives — a fast pulse on the big GLP-1 names plus one molecule unpacked in full. Fridays: the week in review — the biggest stories from the lab, the market, and the regulators, all in about fifteen minutes. Hosted by Jake and Cynthia. For research and informational purposes only — not medical advice.


© 2026 PEPtalk
Hygiene & Healthy Living Science
Episodes
  • 16: Peptalk Deep Dive — KPV Airs Monday, November 16, 2026
    Nov 16 2026

    Three amino acids with an outsized reputation. KPV — lysine, proline, valine — is the last three residues of alpha-MSH, the smallest peptide we've covered, with some of the most consistent gut inflammation data in mice and zero human trials. We unpack what it is, how it works through the PepT1 transporter instead of melanocortin receptors, what the colitis studies actually show, and why the regulatory door has opened a crack.

    GLP pulse: your genes may decide how well semaglutide works (Nature Metabolism, November 11); lower-dose CagriSema posted ~21% weight loss at ObesityWeek (REDEFINE 9) and early responders averaged 25.4% (REDEFINE 1 post-hoc); and a CDC report finds 44% of GLP-1 users changed how they took their medication, most often by skipping doses.

    Next Monday: the KLOW blend vs the GLOW blend, side by side — what does adding KPV buy you?

    Everything we discuss on this show is for research and informational purposes only. Not medical advice. We're describing the science, not recommending anything.

    Sources:

    • Levy et al., Nature Metabolism, November 11, 2026 — rare GLP1R variants and semaglutide vs tirzepatide response: https://www.nature.com/articles/s42255-026-01656-z

    • Novo Nordisk, REDEFINE 9 primary results (ObesityWeek, November 14, 2026) and REDEFINE 1 post-hoc analyses (November 15, 2026): https://www.prnewswire.com/news-releases/novos-cagrisema-was-associated-with-25-mean-weight-loss-among-early-responders-in-a-post-hoc-analysis-of-redefine-1-presented-at-obesityweek-2026-302939681.html

    • CDC, MMWR, November 12, 2026 — Use of GLP-1 Medications and Modified Medication Use Among Adults, United States, 2025: https://www.cdc.gov/mmwr/volumes/75/wr/mm7544a1.htm?s_cid=OS_mm7544a1_w

    • Hiltz ME, Lipton JM. Anti-inflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH. FASEB Journal, 1989: https://pubmed.ncbi.nlm.nih.gov/2550304/

    • Dalmasso G, et al. The PepT1 transporter mediates KPV uptake and reduces intestinal inflammation in colitis models. Gastroenterology, 2008: https://pubmed.ncbi.nlm.nih.gov/18061177/

    • Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases, 2008: https://pubmed.ncbi.nlm.nih.gov/18092346/

    • Xiao B, et al. Hyaluronic acid-functionalized KPV nanoparticles in ulcerative colitis. Molecular Therapy, 2017: https://pubmed.ncbi.nlm.nih.gov/28143741/

    • Brzoska T, et al. Alpha-melanocyte-stimulating hormone and related tripeptides. Endocrine Reviews, 2008: https://pubmed.ncbi.nlm.nih.gov/18612139/

    • FDA Pharmacy Compounding Advisory Committee, July 23, 2026 — KPV recommended for the 503A bulks list (8-6, one abstention).

    • HHS interim enforcement policy, October 28, 2026 — single-ingredient KPV acetate (topical/oral) compounding

    A Spoke-Media production:

    https://www.spoke-media.com


    Show More Show Less
    13 mins
  • Peptalk Week in Review — November 13, 2026
    Nov 13 2026
    This week: the week's biggest story — the FDA orders a class-wide label warning on every GLP-1 drug, from Ozempic to Zepbound, over a rare eye condition, NAION: about 6.4 cases per 100,000 person-years on a GLP-1 against 3.8 on comparison treatments in 126 pooled trials, a small absolute risk with a serious consequence. Plus: the HHS peptide-compounding policy moves from paper to practice as Olympia Pharmaceuticals starts compounding BPC-157 for patients with a prescription, with the public comment window closing November 13 and state pharmacy boards pushing back; Pfizer lands up to $1.5 billion from Blackstone to fund ten Phase 3 trials of its once-monthly GLP-1 shot Berobenatide, with first approvals targeted for 2028; China approves Lilly's Orforglipron (Foundayo), the first GLP-1 weight-loss pill in the country, ahead of Novo's oral Wegovy.And quick hits on Health Canada seizing 11,400+ vials of contaminated unauthorized peptides, Pemvidutide's Phase 2 results in alcohol use disorder, and ObesityWeek opening November 14.For research and informational purposes only — not medical advice. Nothing on this show is a recommendation for any product or treatment.Sources:• U.S. Food and Drug Administration, Drug Safety Communication (Nov 9, 2026) — FDA requires safety labeling changes for GLP-1 receptor agonists due to potential increased risk of NAION (126 randomized trials, 134,253 patients, 15 probable NAION events; 6.4 vs 3.8 per 100,000 person-years): https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential• Pharmaceutical Executive (Nov 10, 2026) — FDA requests updated safety label warning across all GLP-1 receptor agonists for potential risk of NAION: https://www.pharmexec.com/view/fda-requests-safety-label-warning-glp-1-receptor-agonist-risk-naion• Olympia Pharmaceuticals, GlobeNewswire (Nov 12, 2026) — Olympia Pharmaceuticals to compound select peptides under HHS interim enforcement policy (503A pharmacy; BPC-157 first, then KPV, TB-500, MOTS-c, Semax, Epitalon; available by December; licensed in 49 states): https://rss.globenewswire.com/news-release/2026/11/12/3401699/0/en/olympia-pharmaceuticals-to-compound-select-peptides-under-hhs-interim-enforcement-policy.html• Federal Register, Doc. 2026-22192 (Docket HHS-OASH-2026-0496) — HHS enforcement discretion policy for 503A compounding of six peptides; public comment closes November 13, 2026: https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances• Reuters (Nov 11, 2026) — Pfizer secures up to $1.5 billion from Blackstone for obesity drug development (Berobenatide, once-monthly GLP-1; 10 Phase 3 trials; first approvals targeted 2028; Metsera acquisition up to $10 billion): https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-secures-up-15-billion-blackstone-obesity-drug-development-2026-11-11/• BioPharma Dive (Nov 12, 2026) — Blackstone bets $1.5B on Pfizer's obesity drug: https://www.biopharmadive.com/news/blackstone-pfizer-berobenatide-deal/874483/• Reuters (Nov 12, 2026) — Eli Lilly becomes first drugmaker to have a GLP-1 weight-loss pill approved in China (Orforglipron / Foundayo; first oral GLP-1 weight-loss pill approved in China; Novo's oral Wegovy application pending): https://wnflsports.com/2026/11/12/china-approves-eli-lillys-weight-loss-pill-orforglipron/• Health Canada, public advisory RA-82930 (Nov 6, 2026) — Health Canada warns about contaminated unauthorized injectable peptides and non-peptide drugs (11,400+ vials seized from Shanghai ERP Peptide Biotechnology Co. Ltd. and two Canadian online retailers; bacteria including Acinetobacter seifertii, Acinetobacter nosocomialis, Cutibacterium acnes): https://recalls-rappels.canada.ca/en/alert-recall/health-canada-warns-about-contaminated-unauthorized-injectable-peptides-and-non• Health Canada, public advisory (Nov 12, 2026) — Health Canada warns about unauthorized peptides, including contaminated injectable peptides sold by Sage & Summit Wellness Co. in Ottawa, ON: https://www.newswire.ca/news-releases/public-advisory-health-canada-warns-about-unauthorized-peptides-including-contaminated-injectable-peptides-sold-by-sage-amp-summit-wellness-co-in-ottawa-on-802173243.html• Altimmune, GlobeNewswire (Nov 9, 2026) — Altimmune reports positive Phase 2 RECLAIM results for Pemvidutide in alcohol use disorder (heavy drinking days −4.20/week vs −2.75 placebo; 42.2% with zero heavy drinking days vs 17.4% placebo; ~100 adults; presented at AASLD The Liver Meeting 2026, Denver; end-of-Phase 2 FDA meeting planned December 2026): https://www.quiverquant.com/news/Altimmune%20Reports%20Positive%20Phase%202%20RECLAIM%20Results%20for%20Pemvidutide%20in%20Alcohol%20Use%20Disorder%20and%20Announces%20FDA%20Meeting%20Plans%20for%...
    Show More Show Less
    11 mins
  • 14: Peptalk Deep Dive — GHK-Cu
    Nov 9 2026

    The copper peptide in half the serums on your shelf. GHK-Cu is a naturally occurring copper peptide your body already makes — levels highest when you're young, declining with age.

    This week Jake and Cynthia unpack what it is, what the research actually shows for skin, wound healing, hair, and joints, and why the same molecule gets three different regulatory answers depending on the product.

    GLP pulse: Lilly and Hims & Hers strike a direct-sales deal for Zepbound and Foundayo at LillyDirect cash prices — and Hims contractually closes the door on compounded copies of Lilly's GLP-1s.

    Retatrutide posts knee osteoarthritis results from two Phase 3 trials in the New England Journal of Medicine. And the Wegovy pill passes 100,000 prescriptions in its first two months — growing the whole GLP-1 pie instead of cannibalizing it.

    Deep dive: GHK-Cu's proposed mechanism (collagen and elastin, blood-vessel growth, antioxidant and anti-inflammatory effects), the small human studies behind the skin claims, the 2023 diabetic-mouse wound study, the single small 2013 hair study, and the evidence gap everywhere else.

    Plus the safety picture — topicals usually well tolerated, injectables carrying the highest risk — and the FDA's route split: non-injectable compounded GHK-Cu in Category 1 since May 14, 2026 (enforcement policy, not approval), injectable GHK-Cu with its nomination withdrawn and an FDA immunogenicity warning, and GHK-Cu absent from the HHS draft peptide policy's six names.

    Next Monday: KPV, the standalone peptide — then the KLOW versus GLOW comparison on November 23, where GHK-Cu returns as one of four.

    Everything we discuss is for research and informational purposes only. Not medical advice.

    Sources:

    - GoodRx, "GHK-Cu for Skin, Hair, and Healing: What Does the Research Show?" by Patricia Pinto-Garcia, MD, MPH, medically reviewed by Sophie Vergnaud, MD, published November 2, 2026 — https://www.goodrx.com/health-topic/peptides/what-is-ghk-cu

    - DPS Law, "Is GHK-Cu (Copper Peptide) Legal? 2026 Status," November 2, 2026 — https://dpslaw.com/insights/is-ghk-cu-legal

    - U.S. Food and Drug Administration, "Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act," updated May 14, 2026 — https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-federal-food-drug-and

    - U.S. Department of Health and Human Services, "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances," 91 FR 68526 (October 30, 2026)

    - Eli Lilly / PR Newswire via Morningstar, "Lilly and Hims & Hers Expand Access to FDA-Approved Lilly Medicines," November 6, 2026 — https://www.morningstar.com/news/pr-newswire/20261106de90839/lilly-and-hims-hers-expand-access-to-fda-approved-lilly-medicines

    - Reuters via SRN News, "Lilly to Sell Obesity Drugs Directly on Hims & Hers Site," November 6, 2026 — https://srnnews.com/lilly-to-sell-obesity-drugs-directly-on-hims-hers-site/

    - MedicalXpress, "Experimental weight-loss drug eases painful knee osteoarthritis in two clinical trials," November 8, 2026 — https://medicalxpress.com/news/2026-11-experimental-weight-loss-drug-eases.html

    - Jastreboff et al., "Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity" (TRIUMPH-1), New England Journal of Medicine, 2026; TRIUMPH-4 presented at the American College of Rheumatology annual meeting, Orlando, November 2026

    - Healio, "GLP-1 prescriptions for obesity have increased rapidly since introduction of Wegovy pill," November 6, 2026 — https://www.healio.com/news/primary-care/20261106/glp1-prescriptions-for-obesity-have-increased-rapidly-since-introduction-of-wegovy-pill

    A Spoke-Media production:

    https://www.spoke-media.com


    Show More Show Less
    11 mins
adbl_web_anon_alc_button_suppression_t1
No reviews yet